Dendritic cell-derived exosomes: A new horizon in personalized cancer immunotherapy?

Ghorbaninezhad, Farid; Alemohammad, Hajar; Najafzadeh, Basira; Masoumi, Javad; Shadbad, Mahdi Abdoli; Shahpouri, Mohammad; Saeedi, Hossein; Rahbarfarzam, Omid; Baradaran, Behzad

doi:10.1016/j.canlet.2023.216168

Cited by 16 publications

(6 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This construct not only increased cytokine production in vivo but also induced high MUC1specific IgG antibody titers with strong binding affinity for MUC1-positive tumor cells [139]. Exosome-mediated immunotherapy has gained significant attention recently and exhibits remarkable potential as a treatment option for gliomas [140].…”

Section: Utilization Of Inherent Characteristics Of Exosomesmentioning

confidence: 99%

Exosomes in Glioma: Unraveling Their Roles in Progression, Diagnosis, and Therapy

Yang,

Sun,

Liu

et al. 2024

Cancers

View full text Add to dashboard Cite

Gliomas, the most prevalent primary malignant brain tumors, present a challenging prognosis even after undergoing surgery, radiation, and chemotherapy. Exosomes, nano-sized extracellular vesicles secreted by various cells, play a pivotal role in glioma progression and contribute to resistance against chemotherapy and radiotherapy by facilitating the transportation of biological molecules and promoting intercellular communication within the tumor microenvironment. Moreover, exosomes exhibit the remarkable ability to traverse the blood–brain barrier, positioning them as potent carriers for therapeutic delivery. These attributes hold promise for enhancing glioma diagnosis, prognosis, and treatment. Recent years have witnessed significant advancements in exosome research within the realm of tumors. In this article, we primarily focus on elucidating the role of exosomes in glioma development, highlighting the latest breakthroughs in therapeutic and diagnostic approaches, and outlining prospective directions for future research.

show abstract

Section: Utilization Of Inherent Characteristics Of Exosomesmentioning

confidence: 99%

Exosomes in Glioma: Unraveling Their Roles in Progression, Diagnosis, and Therapy

Yang,

Sun,

Liu

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…The specific interaction with Rab proteins and soluble NSF attachment protein receptor (SNARE) complexes is crucial. It directs the subsequent addressing of multivesicular bodies (MVBs) either to lysosomes for degradation or towards fusion with the plasma membrane, resulting in the extracellular release of exosomes [32][33][34][35][36]. Numerous studies have also shown that phosphoinositides, ceramides and, more generally, the lipid composition of the membrane are key factors for the vesicles biogenesis in MVBs [37,38].…”

Section: Exosomes Biogenesismentioning

confidence: 99%

Exosome-mediated Antigen Delivery: Unveiling Novel Strategies in Viral Infection Control

EL SAFADI,

KREJBICH,

MOKHTARI

et al. 2024

Preprint

View full text Add to dashboard Cite

Exosomes are small subtypes of extracellular vesicles (EVs) naturally released by different types of cells into their environment. Their physiological roles appear to be multiple, and many aspects of their biological activities remain to be understood. These vesicles can transport and deliver a variety of cargoes, including proteins, metabolites, nucleic acids, and lipids. Consequently, it is argued that exosomes may serve as unconventional secretory vesicles, playing a crucial role as important vectors for intercellular communication and the maintenance of homeostasis. Exosome production and content can vary under several stresses or modifications in the cell microenvironment, influencing cellular responses both qualitatively and quantitatively. Thus, the analysis of EVs from multiple biofluids, due to its ease of implementation, has become a booming tool for monitoring various pathologies, particularly cancer, as we shall outline further on. During infectious processes, exosomes are described as double-edged swords, displaying both beneficial and detrimental effects. Indeed, during a viral infection, the production of EVs and circulating exosomes is often enhanced to signal danger, stimulate immunity, and possibly serve as pathological biomarkers. Conversely, viruses can disrupt or hijack the exosome content and production. In this review, we discuss the particular and ambiguous functions of exosomes in infectious contexts. Furthermore, we explore the vectoring capacity of exosomes in light of the extensive literature examining their function in mounting adaptive immune responses. Exosomes provide an interesting platform for antigen presentation and could therefore serve as novel therapeutic targets or be used in vaccine strategies.

show abstract

“… 43 Various immune cells, including antigen‐presenting cells (APCs), NK cells, CD4 and CD8+ lymphocytes, and B‐cells, have been found to produce and release IFN‐γ. 44 , 45 This cytokine has the ability to trigger macrophages and the expression of major histocompatibility complex (MHC) class I or II, as well as APC's costimulatory molecules. 46 …”

Section: Role Of Cytokines and Immune Responses In Anticancer Mechanismsmentioning

confidence: 99%

A potential cure for tumor‐associated immunosuppression by Toxoplasma gondii

Lotfalizadeh,

Sadr,

Morovati

et al. 2023

Cancer Reports

View full text Add to dashboard Cite

BackgroundRecently, immunotherapy has become very hopeful for cancer therapy. Cancer treatment through immunotherapy has excellent specificity and less toxicity than conventional chemoradiotherapy. Pathogens have been used in cancer immunotherapy for a long time. The current study aims to evaluate the possibility of Toxoplasma gondii (T. gondii) as a probable treatment for cancers such as melanoma, breast, ovarian, lung, and pancreatic cancer.Recent findingsNonreplicating type I uracil auxotrophic mutants of T. gondii can stimulate immune responses against tumors by reverse immunosuppression at the cellular level. T. gondii can be utilized to research T helper 1 (Th1) cell immunity in intracellular infections. Avirulent T. gondii uracil auxotroph vaccine can change the tumor's immunosuppression and improve the production of type 1 helper cell cytokines, i.e., Interferon‐gamma (IFN‐γ) and Interleukin‐12 (IL‐12) and activate tumor‐related Cluster of Differentiation 8 (CD8+) T cells to identify and destroy cancer cells. The T. gondii profilin protein, along with T. gondii secreted proteins, have been found to exhibit promising properties in the treatment of various cancers. These proteins are being studied for their potential to inhibit tumor growth and enhance the effectiveness of cancer therapies. Their unique mechanisms of action make them valuable candidates for targeted interventions in ovarian cancer, breast cancer, pancreatic cancer, melanoma, and lung cancer treatments.ConclusionIn summary, the study underscores the significant potential of harnessing T. gondii, including its diverse array of proteins and antigens, particularly in its avirulent form, as a groundbreaking approach in cancer immunotherapy.

show abstract

Dendritic cell-derived exosomes: A new horizon in personalized cancer immunotherapy?

Cited by 16 publications

References 113 publications

Exosomes in Glioma: Unraveling Their Roles in Progression, Diagnosis, and Therapy

Exosomes in Glioma: Unraveling Their Roles in Progression, Diagnosis, and Therapy

Exosome-mediated Antigen Delivery: Unveiling Novel Strategies in Viral Infection Control

A potential cure for tumor‐associated immunosuppression by Toxoplasma gondii

Contact Info

Product

Resources

About